Research
Hormonal
Tirzepatide and GLP-1 RA across all doses had significant increases in gastrointestinal adverse effects compared to placebo.
Clinicians should monitor gastrointestinal side effects in patients treated with tirzepatide and GLP-1 RA.
StrongSupportsmedium confidence
As compared to placebo, tirzepatide and GLP-1 RA across all doses had significant increases in gastrointestinal adverse effects.
Why this rating
Based on a network meta-analysis of 31 randomized controlled trials.
Source
Efficacy and safety of tirzepatide, <scp>GLP</scp>‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis
Xin‐Hui Pan et al. · Obesity · 2024
DOI 10.1002/oby.24002
Meta-analysisCited 58×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →